doi: 10.1093/jnci/92.22.1836 37 AnzanoMASmithJMUskokoviMRPeerCWMullenLTLetterioJJet al
"This concept could reshape how GLP-1RAs are prescribed across different disease states." The field is evolving in four directions at once: oral formulations, multi-agonist combinations, muscle preservation strategies, and expansion into disease areas beyond metabolic medicine
TB-500 is used in laboratory studies to examine actin-related signaling, cellular movement, and structural pathway behavior in controlled experimental models
It helps regulate cellular growth and apoptosis
I see a lot of anecdotal reports of anhedonia and I suspect if a patient already has issues with their dopaminergic system, reward motivation, etc, that they might not be the best candidates for GLP-1 agonists for depression treatment as they can cause anhedonia even in low doses by affecting brain reward pathways and blunting dopamine signaling, often reported as emotional flatness